Value of gym-based group exercise versus usual care for young adults receiving antipsychotic medication: study protocol for the multicenter randomized controlled Vega trial.
Antipsychotics
Community
High-intensity Functional Training
Loneliness
Physical activity
Recovery
Severe mental illness
Stigmatization
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
30 08 2023
30 08 2023
Historique:
received:
16
03
2023
accepted:
07
08
2023
medline:
1
9
2023
pubmed:
31
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
Exercise is recommended to protect physical health among people with severe mental illness and holds the potential to facilitate long-term recovery. An inclusive exercise community provides an opportunity for life skill training and social connectedness and may reduce the experience of loneliness and internalized stigmatization which together may improve personal recovery. Using a pragmatic randomized design, we aim to examine the effectiveness of a gym-based exercise intervention tailored to young adults in antipsychotic treatment (i.e., Vega Exercise Community) compared to usual care. It is hypothesized that the Vega Exercise Community will be superior to usual care for personal recovery at four months. The trial will be conducted at four sites in Denmark from which 400 participants, aged 18 to 35 years, who are in current treatment with antipsychotic medications for the management of schizophrenia spectrum or affective disorders, will be recruited. Participants will be randomized (2:1) to Vega Exercise Community or usual care. Vega Exercise Community includes three weekly group-based exercise sessions hosted in commercial functional training centers delivered by certified Vega instructors. After four months, participants in Vega Exercise Community will be randomized (1:1) to minimal versus extended support with regards to sustained physical activity. Data will be collected at baseline, four, six and 12 months. The primary outcome is personal recovery assessed by Questionnaire about the Process of Recovery at four months. Behavioral symptoms, health-related quality of life, metabolic health, and program costs will be evaluated to further determine the effectiveness and cost-effectiveness of the Vega Exercise Community. Finally, the quality of life and physical and mental health of the participants' primary relative will be evaluated. The results of this trial may have important implications for health, sustained physical activity, and recovery for individuals in treatment with antipsychotics. Given the pragmatic design, positive results may readily be implemented by mental health care professionals to promote exercise as an integrated part of treatment of severe mental illness. Clinical Trials.gov (NCT05461885, initial registration June 29th, 2022). WHO Universal Trial Number (UTN): U1111-1271-9928.
Sections du résumé
BACKGROUND
Exercise is recommended to protect physical health among people with severe mental illness and holds the potential to facilitate long-term recovery. An inclusive exercise community provides an opportunity for life skill training and social connectedness and may reduce the experience of loneliness and internalized stigmatization which together may improve personal recovery. Using a pragmatic randomized design, we aim to examine the effectiveness of a gym-based exercise intervention tailored to young adults in antipsychotic treatment (i.e., Vega Exercise Community) compared to usual care. It is hypothesized that the Vega Exercise Community will be superior to usual care for personal recovery at four months.
METHODS
The trial will be conducted at four sites in Denmark from which 400 participants, aged 18 to 35 years, who are in current treatment with antipsychotic medications for the management of schizophrenia spectrum or affective disorders, will be recruited. Participants will be randomized (2:1) to Vega Exercise Community or usual care. Vega Exercise Community includes three weekly group-based exercise sessions hosted in commercial functional training centers delivered by certified Vega instructors. After four months, participants in Vega Exercise Community will be randomized (1:1) to minimal versus extended support with regards to sustained physical activity. Data will be collected at baseline, four, six and 12 months. The primary outcome is personal recovery assessed by Questionnaire about the Process of Recovery at four months. Behavioral symptoms, health-related quality of life, metabolic health, and program costs will be evaluated to further determine the effectiveness and cost-effectiveness of the Vega Exercise Community. Finally, the quality of life and physical and mental health of the participants' primary relative will be evaluated.
DISCUSSION
The results of this trial may have important implications for health, sustained physical activity, and recovery for individuals in treatment with antipsychotics. Given the pragmatic design, positive results may readily be implemented by mental health care professionals to promote exercise as an integrated part of treatment of severe mental illness.
TRIAL REGISTRATION
Clinical Trials.gov (NCT05461885, initial registration June 29th, 2022). WHO Universal Trial Number (UTN): U1111-1271-9928.
Identifiants
pubmed: 37648977
doi: 10.1186/s12888-023-05086-z
pii: 10.1186/s12888-023-05086-z
pmc: PMC10466717
doi:
Substances chimiques
Antipsychotic Agents
0
Banques de données
ClinicalTrials.gov
['NCT05461885']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
634Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Lancet Psychiatry. 2019 Aug;6(8):675-712
pubmed: 31324560
World J Biol Psychiatry. 2023 Jun;24(5):333-386
pubmed: 36202135
Psychiatry Res. 2020 Feb 5;286:112840
pubmed: 32062521
Clin Psychol Rev. 2020 Mar;76:101815
pubmed: 32062302
Br J Psychiatry. 2014 Sep;205(3):236-43
pubmed: 24855127
Int J Behav Nutr Phys Act. 2011 Oct 21;8:115
pubmed: 22018588
Curr Opin Psychiatry. 2014 May;27(3):167-72
pubmed: 24662959
Early Interv Psychiatry. 2019 Jun;13(3):358-368
pubmed: 30039635
BMC Psychiatry. 2019 Jun 21;19(1):192
pubmed: 31226959
Scand J Med Sci Sports. 2014 Apr;24(2):319-26
pubmed: 23126417
Eur Psychiatry. 2015 Nov;30(8):1028-36
pubmed: 26521223
Lancet Psychiatry. 2019 Feb;6(2):103-114
pubmed: 30635177
Int J Surg. 2011;9(8):672-7
pubmed: 22019563
Eur Psychiatry. 2007 Apr;22(3):177-87
pubmed: 17142014
Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718
pubmed: 21678345
Am J Psychiatry. 2015 Jan;172(1):71-81
pubmed: 25219423
Pharmacoeconomics. 2008;26(2):149-62
pubmed: 18198934
Front Psychiatry. 2018 Dec 21;9:690
pubmed: 30622486
Eur J Appl Physiol. 2016 Sep;116(9):1627-38
pubmed: 27311582
BMC Psychiatry. 2017 Feb 13;17(1):68
pubmed: 28193197
Health Educ Behav. 2004 Apr;31(2):143-64
pubmed: 15090118
BMJ. 2017 Jan 12;356:i6681
pubmed: 28082379
Trials. 2018 Feb 23;19(1):139
pubmed: 29475444
N Engl J Med. 2013 Apr 25;368(17):1594-602
pubmed: 23517118
Med Sci Sports Exerc. 1982;14(5):377-81
pubmed: 7154893
BMJ Open Sport Exerc Med. 2023 Sep 26;9(3):e001658
pubmed: 37780132
World Psychiatry. 2014 Feb;13(1):12-20
pubmed: 24497237
Pilot Feasibility Stud. 2021 Aug 19;7(1):162
pubmed: 34412705
Psychol Med. 2012 Mar;42(3):595-606
pubmed: 21854682
Trials. 2013 Apr 27;14:115
pubmed: 23782862
Sports Med. 2020 Jan;50(1):151-170
pubmed: 31541410
Cult Med Psychiatry. 2011 Mar;35(1):63-82
pubmed: 21153047
J Health Serv Res Policy. 1997 Jan;2(1):14-8
pubmed: 10180648
Sensors (Basel). 2014 Jun 19;14(6):10895-928
pubmed: 24949644
Psychol Med. 2016 Oct;46(14):2869-2881
pubmed: 27502153
Nord J Psychiatry. 2011 Oct;65(5):345-52
pubmed: 21428861
Schizophr Bull. 2016 May;42(3):588-99
pubmed: 26547223
Transl Psychiatry. 2020 Jul 24;10(1):254
pubmed: 32709912
Schizophr Res. 2014 Jul;156(2-3):184-9
pubmed: 24816049
Ann Intern Med. 2013 Oct 15;159(8):560-2
pubmed: 24018844
Acta Psychiatr Scand. 2016 Jul;134(1):83-4
pubmed: 26992143
World Psychiatry. 2019 Feb;18(1):53-66
pubmed: 30600626
J Psychiatr Res. 2014 Sep;56:112-9
pubmed: 24931848
Schizophr Bull. 2018 Jan 13;44(1):114-125
pubmed: 28369646
Gen Hosp Psychiatry. 2020 Jan - Feb;62:13-20
pubmed: 31751931
Lancet Psychiatry. 2016 Aug;3(8):717-729
pubmed: 27265548
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
J Clin Epidemiol. 2003 May;56(5):395-407
pubmed: 12812812
Psychol Assess. 2021 Feb;33(2):111-121
pubmed: 33119375
Psychiatry Res. 2020 Jun;288:112950
pubmed: 32361335
Appl Health Econ Health Policy. 2021 Jul;19(4):579-591
pubmed: 33527304
Ugeskr Laeger. 2015 Jul 27;177(31):
pubmed: 26238009
Ment Health Serv Res. 2001 Sep;3(3):141-53
pubmed: 11718206
Am J Psychiatry. 2015 Apr;172(4):344-52
pubmed: 25827032
Annu Rev Clin Psychol. 2013;9:781-809
pubmed: 23330938
Adv Exp Med Biol. 2020;1228:317-332
pubmed: 32342467